3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Desmoid Tumors
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Carboplatin
47
Etoposide
46
durvalumab
28
atezolizumab
28
Cisplatin
21
Topotecan
19
pembrolizumab
15
PM 01183
15
Nivolumab
12
Specimen Handling
11
anlotinib
9
Radiotherapy
9
Paclitaxel
9
Drug Therapy
9
Temozolomide
8
Magnetic Resonance Spectroscopy
8
AMG 757
8
Radiosurgery
7
Platinum
7
Irinotecan
7
toripalimab
6
olaparib
6
Biopsy
6
Ipilimumab
5
Injections
5
Docetaxel
5
Bevacizumab
5
trilaciclib
4
tremelimumab
4
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled